本文来源:时代财经4月7日,默克宣布获得恒瑞医药自主研发的1类新药SHR7280口服GnRH受体拮抗剂(适应症涵盖医学辅助生殖及妇科领域)在中国大陆地区(不含香港特别行政区、澳门特别行政区和台湾地区)的独家商业化权益。这是双方继PARP1抑制剂HRS-1167达成合作后,在创新药领域的再度携手。根据协议条款,默克公司将向恒瑞支付1500万欧元首付款;在此基础上,恒瑞有权收取许可产品的里程碑付款及在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.